product Image
DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit (Respiratory Disease)
Model Name
-
Series
Molecular Diagnostic (Pathogen Detection)
Data
-
Manufacturer information
provider logo
SOLGENT

DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit, Covid19, Corona virus

Problem with product info?
Update request
Manufacturer
SOLGENT
Brand
-
SKU
125213
Product Name
DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit (Respiratory Disease)
Model Name
-
Size
-
Weight
-
Product Details

DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit

Real-Time OneStep RT-PCR based assay system for detection of 2019-nCoV


[Product Certificate]

KFDA-EUA, U.S FDA EUA, Health Canada EUA, CE-IVD


The DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit is a real-time reverse transcriptase (RT)-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal (throat) swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal aspirates, nasal washes, bronchoalveolar lavage (BAL) fluid and sputum from individuals suspected of COVID-19 by their healthcare provider.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial infection or co-infection with other viruses.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.





Contents

ComponentsSQD52-K100
2X OneStep qRT-PCR Buffer (2019-nCoV)1.0 ml x 1ea
OneStep qRT-PCR Enzyme mix (2019-nCoV)200 ul x 1 ea
Primer & Probe Mixture (2019-nCoV)300 ul x 1 ea
Control Template (2019-nCoV)100 ul x 1 ea
RNase Free Water1.0 ml x 1 ea




Specification

Target virusSARS-CoV-2
Target regionORF1a, N gene
Detection technologyReal-Time OneStep RT-qPCR
Specimen typeNasopharyngeal swab, Oropharyngeal swab, Sputum
Compatible instruments*CFX96™ Real-Time PCR System (Bio-Rad)
ABI 7500 / 7500 Fast Real-Time PCR System (Applied Biosystems)
PCR running time~ 120 mins




Features

- Simple & Rapid detection system: OneStep Multiplex RT-qPCR based detection

- HotStart PCR: high-specificity

- Reliable system: automatic PCR control (not Internal control)

- Easy-to-use master mix: just adding template and Primer/Probe Mix

- Positive control included (Plasmid)





Experimental


Types5' Fluorophore3' Quencher
N geneFAMBHQ1
ORF1aVIC/JOE*BHQ1
PCR control(PCRC)Texas Red/Cal Fluor Red 610*BHQ2
*ABI 7500 / 7500 Fast: JOE, Texas Red │ Bio Rad CFX96™: VIC, Cal Fluor Red 610





Example






Ordering information

TechnologyCat. No.ProductContents
Real-Time PCRSQD52-K100DiaPlexQ ™ Novel Coronavirus (2019-nCoV) Detection KitOneStep qRT-PCR Enzyme mix (2019-nCoV)
2X OneStep qRT-PCR Buffer (2019-nCoV)
Primer & Probe Mixture (2019-nCoV)
Control Template (2019-nCoV)
RNase free Water









More products
SOLGENT
DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit, Covid19, Corona virus
For the past 19 years, SolGent grown as a company specialized in human molecular diagnostics projects. In celebration of its 20th anniversary, the company announced its vision of a new start, “SolGent 2.0” and is growing as a bio leader in the 4th Industrial Revolution. Sturdily amassed genome analysis technology and molecular diagnostic technology have become the prominent foundation of the molecular diagnostic market, and SolGent supply products and services with the highest quality to more than 25 countries including domestic research institutes, examination centers, medical institutions and universities. In particular, as “precision medicine,” which analyzes genomes to prevent and predict diseases, becomes a new medical paradigm, SolGent develops and supplies various genome analysis services including for cancer, and expands and applies these services to agricultural products to build the AG-BIO platform. Based on its innovative technology, SolGent develops NADPH coenzyme fixed quantity measurement products DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit, Covid19, Corona virus
Inquiry